2. Long-Term Safety and Maintenance of Efficacy With Once-Daily Roflumilast Cream 0.05% in 2–5-year-olds With Atopic Dermatitis: Data From a 52-Week Phase 3 Trial (INTEGUMENT-OLE)
4. Efficacy and Tolerability of Roflumilast Cream 0.15% for Atopic Dermatitis: Pooled Subgroup Analysis of Patients With Face/ Eyelid Involvement From Phase 3 INTEGUMENT-1/2 Trials
5. Pooled Safety and Local Tolerability of Roflumilast Cream 0.15% From the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials of Patients With Atopic Dermatitis: Subgroup Analysis of Patients With Prior Inadequate Response, Intolerance, and/or Contraindications to Topical Treatments
6. Long-Term Safety of Ruxolitinib Cream in Adults and Adolescents With Mild to Moderate Atopic Dermatitis: Adverse Events of Interest From the TRuE-AD1 and TRuE-AD2 Phase 3 Studies
7. Long-Term Safety and Disease Control of Ruxolitinib Cream in Children Aged 2 to 6 and 7 to 11 Years With Atopic Dermatitis: Results From the TRuE-AD3 Study
8. 52-Week Disease Control and Safety With As-Needed Application of Ruxolitinib Cream in Children Aged 2 to 11 Years With Moderate and/or More Extensive Atopic Dermatitis: Subgroup Analysis From the TRuE-AD3 Study
10. Dupilumab Is Efficacious in Patients Above and Below 65 Years old With Prurigo Nodularis: Pooled Results From Two Phase 3 Trials (LIBERTY-PN PRIME and PRIME2)
12. Disease and Family Burden of Moderate-to-Severe Atopic Dermatitis in Children Aged <6 Years: Results From the PEDISTAD Registry
13. Long-term safety and efficacy of tralokinumab in adults and adolescents with moderate-to-severe atopic dermatitis treated for up to 6 years
14. Long-term safety and efficacy of tralokinumab in patients 65 years or older with moderate-to-severe atopic dermatitis
15. Real-world effectiveness of tralokinumab in adults with atopic dermatitis: Interim data on improvements in physician-assessed disease severity after up to 9 months of follow-up in the TRACE study
16. Real-world effectiveness of tralokinumab in adults with atopic dermatitis: Interim data on improvements in patient-reported outcomes after up to 9 months of follow-up in the TRACE study
17. Treatment-free disease control after tralokinumab in patients with moderate-to-severe atopic dermatitis
18. Topical pan-JAK inhibition with delgocitinib restores the molecular signature of lesional skin in patients with Chronic Hand Eczema: Insights from a Phase 2a study
19. Delgocitinib cream has negligible systemic exposure in patients with maximal use of delgocitinib cream for the treatment of Chronic Hand Eczema
20. Delgocitinib cream 20 mg/g in patients with Chronic Hand Eczema with skin fissures: efficacy, safety, and pharmacokinetics
21. “Super-response” following treatment with delgocitinib cream 20 mg/g in a subgroup of patients with moderate to severe Chronic Hand Eczema
22. Patient reported outcome measures and symptom improvements across subtypes of Chronic Hand Eczema: outcomes of the phase 3 DELTA 1 and DELTA 2 trials
23. Reduction in Post-Inflammatory Pigmentation in Patients With SoC and Atopic Dermatitis Treated with Dupilumab Monotherapy
25. Improvements in Patient-Reported Outcomes and Quality of Life With Dupilumab Monotherapy in Patients With Skin of Color and Moderate-to-Severe Atopic Dermatitis
26. Dupilumab Monotherapy Improves Dyspigmentation and Xerosis in Patients With Skin of Color and Moderate-to-Severe Atopic Dermatitis
27. Maintenance of Disease Control Over 2 Years in Patients With Atopic Dermatitis Treated With Dupilumab
29. Total IgE Reduction With Dupilumab in Pediatric Moderate-to-Severe Atopic Dermatitis: 1.5-Year Follow-Up Data
30. Patient Perception of Life Course Impairment With Moderate-to-Severe Atopic Dermatitis
31. Impact of Dupilumab on the Lives of Patients With Moderate-to-Severe Atopic Dermatitis
32. Dupilumab use in a liver transplanted patient with severe heart disease and moderate atopic dermatitis - a case report
34. Unfinished Stories: Consequences of Melanoma Clinical Trial Discontinuation and NonPublication
35. Dupilumab treatment of atopic dermatitis leads to sustained reductions in cutaneous Staphylococcus aureus: a case series
36. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies
37. Patients With a Smoking History and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)
38. Patients With Atopic Dermatitis Using Oral Contraceptive Pills or Hormone Replacement Therapy: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)
39. Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)
40. The SCALE-UP Study: Real-World Patient-Reported Effectiveness of Upadacitinib‑Treated Adults With Atopic Dermatitis by Fitzpatrick Skin Type and Race
41. Achieving Optimal Treatment Targets for Skin Clearance and Itch Relief in Older Adults (≥65 Years) with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib Monotherapy: 140-Week Outcomes from Integrated Phase 3 Measure Up 1 and 2 Studies
43. Evaluating the Risk of New-Onset Bullous Pemphigoid Following Dupilumab Treatment for Atopic Dermatitis
44. APPLICATION OF REAL-WORLD EFFECTIVENESS OUTCOMES OF UPADACITINIB FOR ATOPIC DERMATITIS TO CANADIAN TREAT-TO-TARGET CRITERIA: A RETROSPECTIVE MULTICENTER ANALYSIS OF WEEK 16±8 DATA
45. APPLICATION OF REAL-WORLD EFFECTIVENESS OF UPADACITINIB FOR ATOPIC DERMATITIS IN ADULT AND ADOLESCENT PATIENTS TO MINIMAL DISEASE ACTIVITY CRITERIA: A RETROSPECTIVE MULTICENTER ANALYSIS OF WEEK 16±8 DATA
46. Patient Experience and Preferences for Treatments in Atopic Dermatitis: Results from a US Patient Survey
47. Real-Time Sweat Biomarker Monitoring in Atopic Dermatitis Flares Using Wearable pH Sensors
49. Insurance Delays in Atopic Dermatitis are Driven by Age and Treatment History
50. Nemolizumab§ long-term efficacy and safety up to 52 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis
51. Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients With Skin of Color: 24-Week Results From the ADmirable Study
52. Maintenance of Lebrikizumab Efficacy in Patients With Moderate-to-Severe Atopic Dermatitis and Atopic Comorbidities
53. Raising the Bar of Efficacy in Atopic Dermatitis: Lebrikizumab Maintains Depth of Response Over 3 Years in Week 16 Responders
54. Achieving Stability of Response in Skin Clearance and Itch Relief With Lebrikizumab Is Associated With No or Minimal Disease Impact on Quality of Life
55. Patients Maintain Stable Response With No or Minimal Fluctuations During 3 Years of Continuous Treatment With Lebrikizumab During Long-Term Extension Trial
56. Lebrikizumab Improves Patient-Reported Disease Control In Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: 24-week Atopic Dermatitis Control Tool (ADCT) Results From ADapt
57. Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From 11 Trials With Over 3000 Patient-Years of Exposure
59. Variability in Skin Tone Changes by Race and Ethnicity Among US Adults With Atopic Dermatitis
60. Individual Clinical Response Trajectories to Lebrikizumab in Atopic Dermatitis: A Cluster Analysis
61. Exploring the cost outcomes of atopic dermatitis patients in high versus low socioeconomic communities globally: a call to consider social determinants of health when planning management and treatment
62. Treatment Choices in Atopic Dermatitis: Exploring the Disconnect Between Disease Burden and Prescription Use
63. APG990, a Monoclonal Antibody Targeting OX40L, Demonstrates Safety and an Extended Half-Life in Healthy Subjects
64. The Combination of APG777 (Anti-IL-13) and APG990 (Anti-OX40L) Provides Broad Suppression of Inflammatory Cytokines
65. Preclinical Potency, Affinity, and Pharmacokinetics of APG990, a Half-Life Extended Antibody Against OX40L
67. A Real-World Multi-center Retrospective Safety Analysis of Ruxolitinib 1.5% cream in Combination with Systemic Therapies for the Management of Atopic Dermatitis
68. Nemolizumab§ is associated with a low incidence of injection site reactions in the treatment of atopic dermatitis and prurigo nodularis
70. Nemolizumab was associated with rapid and significant improvements in itch and sleep in patients with moderate-to-severe atopic dermatitis: Results from two global phase 3 pivotal studies (ARCADIA 1 and ARCADIA 2)
71. INTEGUMENT-INFANT: A Phase 2, 4-Week, Open-Label Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
72. Atopic Dermatitis Signs and Symptoms With Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.15% or 0.05%: Results From the 52-Week Phase 3 INTEGUMENT-OLE Trial in Patients Aged ≥2 Years
73. Impact of Baseline Disease Severity on the Long-Term Efficacy and Safety of Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis: Interim Analysis of the Long-Term Extension JADE EXTEND Study
74. Long-Term Efficacy of Abrocitinib as Monotherapy Over 96 Weeks in the JADE Clinical Program: Can Oral JAK Inhibition Free Patients From Topical Therapy?